Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy by Kottkamp, Hans
REVIEW
Novel therapeutic concepts
Human atrial fibrillation substrate: towards a
specific fibrotic atrial cardiomyopathy
Hans Kottkamp*
Department of Electrophysiology, Hirslanden Hospital, Witellikerstrasse 40, Zurich 8032, Switzerland
Received 11 March 2013; revised 11 April 2013; accepted 15 May 2013; online publish-ahead-of-print 11 June 2013
The atrial structure/substrate of patients with atrial fibrillation (AF) and clinically similar characteristics can present very differently, and also the
‘phenotype’ (i.e. paroxysmal, persistent, and long standing persistent) of the arrhythmia cannot comprehensively explain these differences. It was
unclear why some patients stay in paroxysmal AF for decades, whereas other patients with the same characteristics progress to persistent AF
within a few months. In this review, evidence is described that AF patients without apparent structural heart disease have a chronic fibrotic
bi-atrial substrate. There is also evidence from intraoperatively obtained specimen analysis, post-mortem autopsy findings, electroanatomic
mapping studies, and delayed enhancement-MRI investigations that a higher mean value of fibrosis is detected in patients with persistent vs. par-
oxysmal AF but that the variability in the extend of fibrosis is always very highwith part of paroxysmal AF patients havingmassive fibrosis and part
of persistent AF patients showing mild fibrosis. In addition, patients undergoing ablation very early after the first AF episodes show already sig-
nificant fibrosis. These data do not support a causal relationship that AF (significantly) produces fibrosis in the sense of ‘AF begets AF’ instead of
being a consequence of the fibrotic process. In patients with mitral stenosis, evidence for reverse atrial remodelling after commissurotomy was
reported, however, in patients with ‘lone’ AF, the atrial substrate progressed after successful AF elimination indicating towards the independent/
progressive disease process of an underlying structural atrial disease called fibrotic atrial cardiomyopathy. Other ‘conventional wisdoms’ also
need to be re-considered including the aetiological role of age and arterial hypertension for human structural atrial remodelling.
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Different substrates for atrial
fibrillation
The observation of tachycardia-induced experimental electrical re-
modelling providing the prerequisites for atrial fibrillation (AF) to
persist led to the landmark concept of ‘AF begets AF’.1 However,
the underlying pathophysiological process of human structural atrial
remodelling remained less completely understood.
The atria of patients with AF and clinically similar characteristics
can present very differently during electroanatomic mapping. Inter-
estingly, even patients with the worst (bi-)atrial substrate may
present with paroxysmal (instead of persistent) AF. Left atrial size,
underlying heart disease, age, and ‘phenotype’ (i.e. paroxysmal, per-
sistent, and long-standing persistent) of the arrhythmia alone
cannot explain these differences. Some patients with no or limited
heart disease stay in paroxysmal AF for decades or ‘forever’,
whereas somepatientswith the sameclinical characteristics progress
to persistent AF directly or within weeks or months (Figure 1). The
experimental concepts of atrial remodelling induced by the arrhyth-
mia itself cannot conclusively explain these differences.
The clinical and pathophysiological differentiation between
patients where the PV trigger in paroxysmal ‘focal’ AF is the only
driver of the disease in a self-perpetuating process and patients with
substrate-based AF as a consequence of, e.g. mitral stenosis with a sig-
nificantly enlarged left atrium seems clear. In addition, there is now
increasing evidence that even in patients with so-called lone or idio-
pathic AF, the AF is an arrhythmic manifestation of a structural atrial
disease which has recently been defined and described as fibrotic
atrial cardiomyopathy (FACM).2,3 Different expressions can be found
from mild (FACM I), moderate (FACM II) to excessive fibrosis
(FACM III), and wide clinical variations from asymptomatic to mul-
tiple arrhythmic manifestations (including AF, left and/or right atrial
re-entrant tachycardia, sinus, and/orAVnode disease). Furthermore,
the seemingly clear role of co-existing structural cardiovascular
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diseases (e.g. hypertension) and also the role of age for human struc-
tural atrial remodelling need to be re-analysed.
Atrial structural remodelling
and atrial arrhythmias
The presence of interstitial (micro-)fibrosis leading to changes in cel-
lular coupling results in spatial ‘non-uniform anisotropic’ impulse
propagation and is a potential cause of atrial activation abnormalities
that may underlie the initiation and perpetuation of re-entrant
arrhythmias including fibrillation.4,5 Importantly, the arrhythmogenic
conduction events were described to occur within very small areas,
e.g. re-entrant circuits were found as small as 0.6 × 2.6 mm in human
atrial bundles.Accordingly, increasedfibrosis as a structural correlate
of AF has been reported in humans using intra-operatively obtained
specimen.6,7Cardiac atrial and/or ventricular fibrosis is characterized
byexcessiveaccumulationof collagenousmaterial in theextracellular
space. Electroanatomic bipolar voltage mapping has been described
todefine the relationshipbetweenanatomic andelectrophysiological
abnormalities in an experimental model8 and is now used in clinical
electrophysiological studies for substrate description. Alternatively,
the utility of delayed enhancement (DE)—magnetic resonance
imaging (MRI) was described in detecting, quantifying and localizing
atrial fibrosis including four categories of structural changes (‘Utah
stages I– IV’)9,10 (Figure 2).
Atrial remodelling in conditions
predisposing to atrial fibrillation
John et al.11 described electroanatomic remodelling of the left and
right atria in 24 patients with rheumatic mitral stenosis undergoing
mitral commissurotomy. Importantly, patients were excluded if
they had any suggestion of atrial arrhythmia/AF or other structural
heart disease besides mitral stenosis. In comparison with 24
control patients, the patients with mitral stenosis showed—beyond
left atrial enlargement—a significantly reduced biatrial voltage (left
atrium 1.8+ 0.6 vs. 3.6+0.6 mV, right atrium 1.9+ 0.6 vs. 3.3+
0.5 mV), reduced conduction velocity, and prolonged effective re-
fractory periods.11 These abnormalities may clearly play a role in
the increased propensity to AF in patients with mitral stenosis.
Indeed, patientswithmitral stenosisweremore susceptible to induc-
tion of AF with extrastimulus provocation. Similar left atrial remod-
elling was described in patients with haemodynamically significant
atrial septal defects (but no AF) compared with control patients in-
cluding significantly reduced left atrial voltage.12
Hypertension is another common co-existing factor which is
described to be associated with AF. Medi et al. 13 described results
from electroanatomic mapping and reported right atrial changes in
10 patients with systemic hypertension plus left ventricular hyper-
trophy (but no AF) compared with 10 control patients. In patients
with chronically treated hypertension, a significant slowing of con-
duction velocity was described. Furthermore, sustained AF was
induced in 30% of hypertension patients but no controls. Overall,
Figure 1 The progression from paroxysmal to persistent atrial fibrillation may be very different in clinically matched patients. (A) 7-day-ECG in a
69-year-old patient with paroxysmal ‘lone’ atrial fibrillation. The patient had a history of paroxysmal atrial fibrillation of 22 years with frequent epi-
sodesperweekorevenperday (asterisks), however, the individual episodes stayedshortwithinminutesormaximally fewhourswithnoevidence for
progression. (B) During sinus rhythm, this patient presentedwith frequent premature atrial complexes with ‘P-on-T’ phenomenon (black asterisks)
and also frequent atrial salvoes (white asterisks). (C) 7-day-ECG in another 69-year-old patient with paroxysmal ‘lone’ atrial fibrillation. This patient
had a short history of atrial fibrillation of only 6 months, however, he presented with atrial fibrillation episodes lasting already .48 h in the initial
7-day-ECG (arrows). Hardly any premature atrial complexes were found during periods of sinus rhythm (not shown). (D) This patient progressed
to persistent atrial fibrillation within only another 3 months.
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the structural changes in hypertensive patients observed in this study
were less pronounced (compared with the changes in patients with
mitral stenosis or atrial septal defect). Importantly, the mean right
atrial voltage as a surrogate for the structural (i.e. fibrotic) atrial re-
modelling was identical in the hypertension and control groups
(2.2+ 0.5 vs. 2.2+0.3 mV).
A chronic bi-atrial substrate in
patients with paroxysmal ‘lone’
atrial fibrillation
The evidence for a chronic and substantial atrial substrate in patients
with lone AF is substantiated by an investigation of extracellular
matrix proteins in left atrial tissue of patients with ‘lone’ AF
(n ¼ 56), with AF plus mitral valve disease (n ¼ 46), and with sinus
rhythm (n ¼ 16).7 Left atrial tissue was obtained from atriotomy
during cardiac surgery. The association of human AF with fibrosis
was shownwith collagen concentrations being significantly increased
inpatientswithAFcomparedwith those in sinus rhythm. Importantly,
collagen I—which is the major collagenous product of cardiac
fibroblasts—was enhanced in ‘lone’ AF patients even to a similar
extent compared with AF in patients with severe mitral valve
disease (Figure 3).
Stiles et al.14 investigated 25 patients (53+ 8 years) with ‘lone’ AF
during an electrophysiological study after at least 7 days in sinus
rhythmand found slowerconductionvelocity, longereffective refrac-
tory periods, and—importantly—significantly lower voltages (left
atrium 1.7+0.7 vs. 3.3+ 0.7 mv, right atrium 1.7+0.4 vs. 2.9+
0.4 mV) compared with control patients without AF. These findings
confirma substantial chronic structural bi-atrial substrate since the elec-
trical remodelling is reversiblewithin a fewdays.15 It might be that not
all patients with paroxysmal ‘lone’ AF have an (underdetected)
chronic substrate, but many more then assumed (Figure 4).
The findings of a chronic substrate in patients with paroxysmal
‘lone’ AF were recently extended in a DE-MRI study of the left
atrial substrate.16 In that study, 40 of 333 included patients met
criteria for ‘lone’ AF. The majority of these ‘lone’ AF patients
showed a mild or even moderate degree of left atrial fibrosis,
thereby compatible with mild/moderate and/or early forms of
FACM I/II.
Is mild-to-moderate left atrial fibrosis necessary on top of PV trig-
gers for AF to sustain for hours or days? Clinically, the time relation-
ship of the trigger initiating AF and the substrate taking over for
maintaining AF is largely unknown. Evidence for short trigger activity
came from a study investigating a surgical left atrial linear lesion
concept targeting at the prevention of anatomic left atrial re-entry
without PV isolation in patients with paroxysmal and persistent
AF.17 After a mean follow-up of 3.6 years, atrial ectopy, atrial runs,
Figure 2 Quantification of left atrial structural remodelling with delayed enhancement magnetic resonance imaging (‘Utah I– IV’). Posterior-
anterior and anterior-posterior view of enhancement (green) vs. normal tissue (blue) in patients with ‘lone’ atrial fibrillation (Courtesy of Nassir
F. Marrouche, M.D., CARMACenter, Salt Lake City).
Figure 3 Collagen I expression in left atrial tissue of patients in
sinus rhythm, with ‘lone’ atrial fibrillation, and with atrial fibrillation
plus mitral valve disease. Collagen I was enhanced in ‘lone’ atrial fib-
rillation patients to a similar extent when compared with atrial fib-
rillation in patients with severe mitral valve disease (modified from
Boldt et al.7)
Fibrotic atrial cardiomyopathy 2733
and re-occurrence of AF episodes were analysed by 7-day-ECGs in
30 patients. Overall, 87% of the patients were free from AF.
However, atrial ectopy was present in all patients and atrial runs in
83% of the patients with a median of 9 runs per patient/week
(range, 1–321). Importantly, the median duration of the atrial runs
as a surrogate for the duration of PV trigger activity measured only
1.2 s (range, 0.7–25). This may indicate that a chronic atrial substrate
is indeed necessary for even relatively short episodesofAF to sustain.
More atrial substrate in patients
with persistent vs. paroxysmal
atrial fibrillation? Fibrotic changes
as cause fororconsequenceof atrial
fibrillation?
If the clinical AF episodes were the critical stimulus for the develop-
ment of structural (fibrotic) remodelling, then there should be a step-
wise increase with longer history and/or longer episodes of AF
(higher cumulative AF burden), and especially a clear increase in fi-
brosis when patients with paroxysmal and persistent AF are com-
pared. However, this does not seem to be the case.
Differences in patients with paroxysmal and persistent AF were
analysed in the study with left atriotomy specimen obtained during
cardiac surgery.7 Importantly, therewas a similar degree of enhanced
collagen expression in paroxysmal andpersistentAF (Figure 5).While
there was a tendency of an increased mean fibrosis level in patients
with persistent AF vs. paroxysmal AF, the variation within the two
groups was clearly very high and a statistical difference in fibrosis
extent, therefore, could not be demonstrated.
Platonov et al.18 confirmed and extended the results from Boldt
et al. by investigating structural abnormalities in post-mortem
autopsy atrial specimen from 30 patients in three age-matched
groups of patients without AF history, with paroxysmal AF, or with
permanent AF. Atrial tissue samples were collected from the right
atrium, Bachmann’s bundle, and from the posterior left atrial wall.
Figure 4 Electroanatomic left atrial voltage mapping in two patients with paroxysmal ‘lone’ atrial fibrillation. (A) The patient had a long history of
paroxysmal atrial fibrillation of 12 years, however, the duration of the atrial fibrillation episodes remained very short and the voltagemap still shows
no evidence at all of fibrosis. These fibrosis-free maps are found in our experience in,10% of patients with paroxysmal ‘lone’ atrial fibrillation. (B)
This patient had averyshort historyof PAFofonly 7months. Since thepatientwasextremely symptomatic, anoverall cumulative frequencyof 10–12
atrial fibrillation episodes could be estimated. However, the fibrotic atrial cardiomyopathy processwas already substantial withmoderate fibrosis at
the timeof the clinical adventof paroxysmal atrial fibrillation. Projections fromanterior andposterior are given.Voltages ofmapping points.2.5 mV
are annotated purple (normal voltage), voltages,0.5 mV are indicated red (severely reduced voltage). LPV andRPV, left and right pulmonary veins.
Figure 5 Collagen I expression in human atrial tissue from
patients with sinus rhythm, ‘lone’ paroxysmal atrial fibrillation and
persistent (CAF) atrial fibrillation, and in patients with mitral valve
diseaseplus sinus rhythm, paroxysmal atrial fibrillation, andCAF, re-
spectively. Note, the overlapping wide variation/range of collagen I
in patients with paroxysmal atrial fibrillation and CAF, with some
paroxysmal atrial fibrillation patients having excessive fibrosis
(asterisks) and some CAF patients having mild fibrosis (double
asterisks) (modified from Boldt et al.7).
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Patientswith anyhistoryofAFhad a three- tofive-fold greaterextend
of fibrosis comparedwith patients without AF history. A comparison
revealed a greater extent of fibrosis in patients with permanent AF
compared with patients with paroxysmal AF. However, these differ-
ences were statistically significant in the left atrial tissue specimen
only at the superior PV level, whereas no significant differences
between patients with paroxysmal and permanent AF were found
in the posterior left atrial wall and at the inferior PV level.18 Import-
antly, the variation in the data obtained from the posterior level
between patients with paroxysmal and permanent AF were very
high. In addition, the extent of fibrosis showed no clear correlation
with the duration of AF history.
Recently, Teh et al.19 described electroanatomic remodelling of the
left atrium in paroxysmal (n ¼ 17) and persistent (n ¼ 14) AF patients
without structural heart disease comparedwith control patients (n ¼
15).Again, a lowervoltage in theAFpatientswas foundcomparedwith
the control patients. The mean left atrial voltage difference between
patients with paroxysmal and persistent AF even reached a low statis-
tical difference, however, in half of the left atrial areas that were inves-
tigated, this difference was not statistically significant.
Oakes et al.9 reported on the DE-MRI quantification of left atrial
structural remodelling in 81 patients with AF. Mild enhancement
was found in 43 patients, 28 of these (65%) had paroxysmal AF.
However, 15 of these patients (35%) still had onlymild enhancement
but were already in persistent AF. Furthermore, from the 30 patients
with moderate enhancement, 43% still presented with paroxysmal
and 57% with persistent AF, respectively, again indicating towards
the high variability of structural remodelling in patients with paroxys-
mal and persistent AF.
Atrial fibrillation and the
association to age and other
co-existing cardiovascular diseases
From an epidemiological point of view, human ageing certainly is asso-
ciated with an increased likelihood of developing AF.20 However, a
potential causative aetiological relationship of human age and devel-
opment of AF is far less well established. Indeed, data on qualitative
and quantitative analyses of bi-atrial human tissue from patients
with non-valvular AF are scarce. In the human autopsy investigation,
Platonov et al.18 reported on the association between structural
changes in the human atria, age, and history of AF. In contradiction
to the ‘conventional wisdom’ about the association between
human age and atrial fibrosis, Platonov et al. were not able to
detect any correlation between patient age and increase in fibrosis
extent. Furthermore, atrial samples from age-matched arrhythmia-
free patients contained ‘negligibly’ low amounts of fibrofatty tissue,
even in very old patients. These autopsy results match well with
data from an electroanatomic mapping study investigating the
impact of age on left and right atrial voltage.21 In that study, the
mean bipolar voltage in young patients ≤40 years was somewhat
higher compared with older patients; however, there were hardly
any differences in the age group 51–60 compared with 61–70 and
beyond 70 years. Furthermore, age was also equally distributed in
the four DE-MRI fibrosis grade groups (mean age 69 years in the
total non-lone AF group, 68 years in the Utah I group, 66 years in
the Utah II group, 68 years in the Utah III group, and 70 years in the
Utah IV group, respectively).16
Similar to the assumed aetiological association of human ageing and
AF, co-existing cardiovascular diseases (e.g. hypertension) are also
thought to play an important aetiological role in the development of
AF. Mahnkopf et al.16 compared the left atrial structural changes using
DE-MRI in patients with ‘lone’ AF (n¼ 40) vs. those with ‘classical’ co-
morbidities (n¼ 293). Importantly, thedegreeof left atrial structural re-
modelling was found to be completely independent of co-morbidities.
Furthermore, thedistributionofgroupsUtah I–IVshowednosignificant
differences between patients with lone AF and non-lone AF. For
example, fibrosis grade Utah II was found in 65 vs. 64% of lone AF and
non-lone AF patients, and fibrosis grade Utah III in 23 vs. 23% of lone
AFandnon-loneAFpatients, respectively.16 In addition, co-existing car-
diovascular diseases were equally distributed in the four fibrosis grade
groups, e.g. hypertension in 66% of patients of the total non-lone AF
group, in 76% of the Utah I group, in 67% of the Utah II group, in 61%
of the Utah III group, and in 68% of the Utah IV group, respectively.
These data thereby confirm the autopsy study data, where the co-
morbidity status expressed in the CHA2DS2-VASc score measured
3.8+1.8 in patients with AF vs. 4.3+1.9 in patients without AF.18
These data also confirm results from electroanatomic mapping,
where no atrial voltage differences could be detected in patients with
(arrhythmia free) hypertension patients vs. control patients.13
Evidence for reverse human atrial
structural remodelling?
John et al.22 investigated the potential for reverse human atrial remod-
elling in 21 patients undergoing mitral commissurotomy for treat-
ment of severe mitral stenosis. Bi-atrial voltage mapping was
performed before and after commissurotomy—and in 14 patients,
right atrial mapping was repeated after ≥6 months. Importantly, a
further significant increase in atrial voltage was demonstrated late
after interventional treatment from 1.8+0.7 to 2.8+0.6 mV.
Therefore, late after reversal of chronic stretch, a progressive im-
provement in bipolar voltage could be shown indicating the potential
for reverse human atrial remodelling.
If AF itselfwere the stimulus for the development of this fibrotic sub-
strate in patients without structural heart disease, it could be hypothe-
sized that this substrate was reversed after successful AF elimination.
Teh et al.23 performed right atrial electroanatomic maps in 11 control
patients and 11 ‘lone’ AF patients undergoing catheter ablation at base-
line plus ≥6 months following successful elimination of AF. The sub-
strate did not appear to reverse after successful ablation of AF. In
contrast, there was a progressive substrate remodelling 6–14 months
after successful catheter ablation with further decrease in atrial




Electroanatomicmapping andDE-MRI are potential clinical diagnostic
tools. Electroanatomic mapping, however, has all limitations of
Fibrotic atrial cardiomyopathy 2735
invasive procedures and does not allow diagnostic follow-up investi-
gations. In contrast, the potential of DE-MRI for detecting and quan-
tifying atrial fibrosis looks attractive as a non-invasive, repeatable
diagnostic tool. Recently, pre-operatively elevated serum markers
of collagen synthesis (PICP) have been reported to be associated
with post-surgical AF.24 Furthermore, a linear correlation between
PICP and left atrial fibrosis was described. This raises the potential
option of identifying subclinical FACM in general before the advent
of AF. Overall, the definition and the understanding of the term
‘lone’ AF needs to bemodified in the future. FACM to date is difficult
to detect by conventional means but constitutes a substantial and
chronic structural atrial diseaseposing thepatient to the riskof devel-
oping AF and other manifestations.3
Genetics seem toplay a key role in FACM.A familiar aggregation of
loneAF inyoungpersonshasbeendescribed recently.25 Frequently, a
familiar appearance of clinical findings indicating towards FACM can
be observed. However, genetic analyses of specific subgroups of
AF so far are limited. Besides the key player genetics, additional
pathophysiological aspects might include an inflammatory process
as indicated by studies from Frustaci et al.26 on biopsy findings in
patients with lone AF, Chung et al.27 on C-reactive protein elevation
in patientswith atrial arrhythmias, and findings on the role of steroids
to prevent AF recurrences after ablation.28
In patients with ‘pure’ focal AF (i.e. without atrial fibrosis), PV iso-
lation can be considered a curative treatment option. In patients with
the potentially progressive disease FACM, where AF is a manifest-
ation of a structural atrial disease, catheter ablation can also effective-
ly treat AF but ablation cannot be considered curative. Verma et al.29
reported that pre-existent left atrial scarring in patients undergoing
ablation was an independent predictor of procedural failure, which
was confirmed in DE-MRI studies.9,10 Progressive atrial remodelling
after ablation in FACM cases may explain late recurrences despite
durable PV isolation and development of ‘new’ arrhythmias. In add-
ition, the association of left atrial fibrosis and the risk of stroke in
patients with AF will need to be considered for oral anticoagulation
strategies in the future.3,30
Fibrotic atrial cardiomyopathy:
summary and outlook
There is substantial evidence that themajority of patientswithout ap-
parent structural heart disease (so-called ‘lone’ AF) has a chronic fi-
brotic bi-atrial substrate.7,14,16 A higher mean value of fibrosis is
detected in patients with persistent vs. paroxysmal AF.7,9,18,19
However, the variability in the extend of fibrosis in patients with
Figure6 Electroanatomic left atrial voltagemapping in patients with ‘lone’ paroxysmal (A–D) and persistent (E–F) atrial fibrillation. The electro-
anatomicmaps of the patients with paroxysmal atrial fibrillation show awide variation of voltage distributionwith no correlation to atrial fibrillation
history duration: (A) no fibrosis; (B) mild fibrosis; (C) moderate fibrosis; (D) extensive fibrosis. (E and F) Also in patients with persistent atrial fibril-
lation, a wide variation of voltage distribution is found. Projection from anterior and posterior is given. Voltages of mapping points .2.5 mV are
annotated purple (normal voltage), voltages ,0.5 mV are indicated red (severely reduced voltage). LPV and RPV, left and right pulmonary veins.
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paroxysmal and persistent AF is very highwith part of paroxysmal AF
patients having massive fibrosis as well as part of persistent AF
patients showing mild fibrosis.7,9,18,19 Thus, these data do not
support a causal relationship that AF (significantly) produces fibrosis
in the sense of ‘AF begets AF’ instead of being a consequence of the fi-
brotic process in FACM (Figure 6). There are obviously patients with
‘lone’ AF, where the substrate is already very advanced with massive
bi-atrial fibrosis before the advent of AF.3 Accordingly, no clear cor-
relation could be demonstrated between the extend of fibrosis and
the duration of AF history.16,18 The analysed studies with different
methodologies are very consistent, however, the relatively small
sizeof someof these studiesnecessitates confirmationandextension
in future trials.
Other ‘conventional wisdoms’ also need to be re-considered. In
the autopsy investigation specifically addressing the role of age, no
correlation at all could be detected between patient age and fibrosis
extent.18 Instead, the clinical manifestation of FACM with cardiac
arrhythmias in most patients occurs in advanced ages (≥60 years)
and less frequently in younger ages. In the same line, the degree of
left atrial structural remodelling was found to be independent of co-
morbidities (e.g. hypertension, diabetes) in DE-MRI and autopsy
studies.16,18Given these results that age and ‘classical’ co-morbidities
have no association with the extent of atrial fibrosis, these data all in-
dicate that the chronic bi-atrial substrate of patients with AF is the
result of a specific FACM. Further striking evidence for the existence
of FACM in patients with ‘lone’ AF comes from electroanatomic
mapping studies on the reversibilityof human atrial structural remod-
elling.22,23 In patients with mitral stenosis, there was clear evidence
for reverse atrial remodelling after commissurotomy. However, in
patientswith ‘lone’AF, the atrial substrateprogresseddespite success-
ful AF elimination indicating towards the independent and potentially
progressive disease process of FACM.
Different expressions of the FACM disease exist from
mild-to-severe fibrosis (FACM I–III), andwithwide clinical variations
from asymptomatic cases to cases with multiple arrhythmic manifes-
tations, atrial mechanical dysfunction as well as thromboembolic
complications.3 Clinically, the co-existence of sick sinus node plus
paroxysmal AF (‘bradycardia–tachycardia–syndrome’) is the most
frequent FACM manifestation combination.3,31
Recently, localized electrical ‘rotors’ have been described as
prevalent sustaining mechanisms of human AF, and catheter ablation
at patient-specific sources improved clinical outcome.32 It might be
speculated that these patient-specific sources correlate with areas
of atrial fibrosis where the site-specific micro-architecture of con-
nective tissue fibres and the remaining myocardial fibres allows re-
entrant/rotor activation to occur and to sustain. The combination
of localizing atrial fibrosis plus mapping of specific functional areas
allowing re-entrant/rotor activation may hold promise for catheter-
based AF substrate modification in the future.
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Epicardial Wolff–Parkinson–White ablation
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A 45-year-old female patient without structural
heart disease was referred for redo Wolff–
Parkinson–White (WPW) ablation after an unsuc-
cessful endocardial procedure. The refractory
period of the accessory pathway had been mea-
sured at 230 ms and antiarrhythmic treatment
with flecainide was unsuccessful.
(1) The surface electrogram shows the largest
negative d-wave in lead III.
(2) During endocardial mapping of the ventricular
insertion the earliest activation was found
near the coronary sinus ostium (x); however,
radiofrequency application was not successful.
Note the morphology of the unipolar signal
(Abl uni) with an initially positive small spike
(red arrow) resulting fromepi-endocardial acti-
vation followed by the broad negative ventricu-
lar activation signal.
(3) Epicardial mapping via subxiphoidal access
showed the earliest signal (XX) opposite to the endocardial site (X). The distance between the two locations was 1.5 cm. Note
the morphology with an entirely negative small pathway spike (red arrow) followed by the broad negative ventricular activation
signal. Irrigated radiofrequency ablation was successful after 25 s and increase of power from 20 to 30 W.
Epicardial access can be necessary, if the largest negative d-wave is in lead III on the surface ECG. The morphology of the unipolar signal
indicates the trueepicardial origin of the ventricular pathway insertion. Success canbeobservedevenafter delayed response toRFdelivery.
In Panel 1: ECG, electrocardiogram; LAO, left anterior oblique; Abl, ablation electrode; CS, coronary sinus; CSp, coronary sinus elec-
trode proximal; CSd, coronary sinus electrode distal; RV, right ventricular electrode; LAT, local activation time measured relative to
onset of QRS signals on surface ECG. The local activation time is measured conventionally (middle) and visualized in a coloured
Carto-3D map (red earliest).
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